Skip to main content
. 2022 Jun 25;29(7):4478–4510. doi: 10.3390/curroncol29070356

Figure 1.

Figure 1

In a bid to raise awareness of the disease, a multidisciplinary group of experts recommended changing the definition and nomenclature of NAFLD to metabolic dysfunction-associated fatty liver disease (MAFLD). MAFLD is diagnosed in patients with steatosis and at least one of the three criteria: obesity/overweight, type 2 diabetes mellitus and any evidence of metabolic dysregulation. NAFLD—non-alcoholic fatty liver disease; MAFLD—metabolic dysfunction-associated fatty liver disease.